VTCN1 and breast carcinoma: On the basis of the difference in tumor progression, or lack thereof, in the human cohorts and mouse models, future understanding of the mechanisms of B7-H4 in vivo are essential to rule out or include B7-H4 as a potential biomarker for future patients with breast cancer.